Technical Analysis for IBIO - iBio, Inc.

Grade Last Price % Change Price Change
grade C 0.87 -1.14% -0.01
IBIO closed down 1.14 percent on Friday, January 18, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical IBIO trend table...

Date Alert Name Type % Chg
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Down 3 Days in a Row Weakness 0.00%
Jan 17 Stochastic Sell Signal Bearish -1.14%
Jan 17 Wide Bands Range Expansion -1.14%
Jan 17 Overbought Stochastic Strength -1.14%
Jan 16 Jack-in-the-Box Bullish Bullish Swing Setup -3.33%
Jan 16 Inside Day Range Contraction -3.33%
Jan 16 Wide Bands Range Expansion -3.33%
Jan 16 Overbought Stochastic Strength -3.33%

Older signals for IBIO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States. Its product portfolio includes seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus. The company also offers biodefense products, including oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates comprising human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. Further, the company offers vaccine enhancements through its iBioModulator platform. It has a license and collaboration agreement with Caliber Biotherapeutics, LLC for the development and production of recombinant plant-based biopharmaceuticals. The company is headquartered in Newark, Delaware.
Is IBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.497
52 Week Low 0.495
Average Volume 66,741
200-Day Moving Average 1.005
50-Day Moving Average 0.7562
20-Day Moving Average 0.7646
10-Day Moving Average 0.845
Average True Range 0.0913
ADX 17.0
+DI 20.7596
-DI 15.8575
Chandelier Exit (Long, 3 ATRs ) 0.6761
Chandelier Exit (Short, 3 ATRs ) 0.7689
Upper Bollinger Band 0.9718
Lower Bollinger Band 0.5574
Percent B (%b) 0.75
BandWidth 54.198274
MACD Line 0.0431
MACD Signal Line 0.0281
MACD Histogram 0.015
Fundamentals Value
Market Cap 80.75 Million
Num Shares 92.8 Million
EPS -0.16
Price-to-Earnings (P/E) Ratio -5.30
Price-to-Sales 74.56
Price-to-Book 3.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.99
Resistance 3 (R3) 0.99 0.95 0.97
Resistance 2 (R2) 0.95 0.92 0.95 0.96
Resistance 1 (R1) 0.91 0.90 0.93 0.91 0.96
Pivot Point 0.87 0.87 0.88 0.87 0.87
Support 1 (S1) 0.83 0.84 0.85 0.83 0.78
Support 2 (S2) 0.79 0.82 0.79 0.78
Support 3 (S3) 0.75 0.79 0.77
Support 4 (S4) 0.75